The metabolic-syndrome thesis: one upstream cause for many downstream diseases

TL;DR. In 1988, Stanford doctor Gerald Reaven gave a famous talk called the Banting Lecture. He said five problems — obesity, type 2 diabetes, high blood pressure, bad cholesterol, and high blood sugar — were not five separate diseases. They were branches of one root problem: insulin resistance. He called it Syndrome X. Today we call it metabolic syndrome (MetS). Thirty years later, Robert Lustig, Casey Means, and Gary Taubes go further. They say most chronic Western diseases share this same root, including fatty liver, PCOS, Alzheimer's, heart disease, gout, and several cancers. If they are right, doctors are treating thirty symptoms of one disease. Drug companies are chasing branches instead of the trunk. And the best fix is food.

What you'll learn

• The Reaven 1988 Banting Lecture and how Syndrome X became metabolic syndrome.
• The single-cause hypothesis — why so many Western diseases plausibly share insulin resistance as upstream cause.
• Lustig's eight cellular pathologies and why they are nutrient-sensing rather than druggable.
• Casey Means's mitochondrial framing — Bad Energy as cellular ATP deficit preceding diagnosis.
• Inflammation as connective tissue (Calder, Modern Nutrition in Health and Disease Ch 65) across cardiovascular, metabolic, oncologic, and neurologic disease.
• The Means / Lustig / Taubes convergence on fructose, chronic insulin signaling, omega-6:3 imbalance, and sedentary life.
• Why pharma has failed against this cluster, and why dietary interventions outperform single-target drugs.

1. Reaven 1988 — the founding paper

The thesis has a birth date: 7 June 1988, San Francisco. Gerald M. Reaven, a Stanford doctor who studied insulin for 20 years, gave the Banting Lecture. The Banting Lecture is the top honor from the American Diabetes Association. It is named for the man who helped discover insulin. Reaven's talk was published that year in Diabetes as "Banting Lecture 1988: Role of Insulin Resistance in Human Disease." It is one of the most-cited papers in the field.

Reaven's argument was simple. He looked at five problems that doctors studied as separate diseases: belly fat, type 2 diabetes, high blood pressure, bad cholesterol (high triglycerides plus low HDL), and high blood sugar. He showed these five problems showed up together far more often than chance would predict. He called the cluster Syndrome X. He picked an open name so the field could add to it later. The link he proposed was insulin resistance: your muscle, liver, and fat cells stop responding to insulin. So your pancreas pumps out more to keep your blood sugar in range.

Here is how the chain works. Insulin resistance pushes your pancreas to make more insulin. This is called hyperinsulinemia (too much insulin in your blood). High insulin tells your kidneys to hold on to salt and water, which raises blood pressure. It tells your liver to pack extra fuel into triglyceride-rich VLDL particles. That lowers your HDL and shifts your LDL toward small, dense, artery-clogging particles. It pushes fat into your liver, pancreas, and muscle, where fat is not supposed to live. After 10 to 20 years of this, your pancreas wears out. Your blood sugar starts to rise. A doctor finally says, "You have type 2 diabetes."

Doctors agreed on five criteria from the NCEP Adult Treatment Panel III (ATP III) in 2001, with a 2005 update. ATP III stands for the National Cholesterol Education Program's third expert report. If you meet any three of these five, you have metabolic syndrome:

• Waist over 40 inches (men) or 35 inches (women)
• Fasting triglycerides at or above 150 mg/dL
• HDL cholesterol below 40 (men) or 50 (women)
• Blood pressure at or above 130/85
• Fasting glucose at or above 100 mg/dL

These five are not random. Each one tracks back to insulin resistance.

2. The single-cause hypothesis

Reaven was careful. He taught that insulin resistance was the upstream cause of a small cluster of problems. The bigger claim — that most chronic Western disease shares one root — came later. Lustig and Means built that case piece by piece.

The list now plausibly includes:

• Type 2 diabetes.
• Nonalcoholic fatty liver disease (NAFLD), a buildup of fat in your liver. It was almost unheard of before 1980. About 75 million U.S. adults have it now.
• Heart disease. Insulin resistance tracks your risk better than LDL cholesterol does.
• High blood pressure, driven by insulin telling your kidneys to hold salt, and by uric acid from fructose.
• Polycystic ovary syndrome (PCOS), where high insulin drives your ovaries to make extra male hormones.
• Gout, where fructose raises uric acid and insulin resistance keeps your kidneys from clearing it.
• Many cancers. Liver, pancreas, colon, breast, and uterus tumors grow with insulin and IGF-1. Tumors also burn glucose in a weird way called the Warburg effect.
• Late-onset Alzheimer's. Some call it "type 3 diabetes." Type 2 diabetics have 1.5 to 2 times the dementia risk. The brain shows clear insulin-signaling problems.

Hu and colleagues in 2001 (J Am Coll Nutr) made the case that diet quality — not just calories or BMI — drives the syndrome. Data from the Nurses' Health Study and the Health Professionals Follow-up Study showed something striking. The same diets that raise type 2 diabetes risk also raise heart disease, several cancers, and cognitive decline. High sugar drinks, low fiber, few whole grains, low omega-3. The diseases group together at the food level, not just the patient level.

The strongest test of the single-cause idea is this: if you fix the root, do the downstream diseases improve together? They do. Bariatric surgery resolves type 2 diabetes within days, often before much weight loss. The Newcastle 800-calorie diet (Lim et al., 2011) put about 90 percent of new type 2 diabetics into remission. DiRECT (Lean et al., Lancet 2018) showed 46 percent remission at one year in primary care. Virta Health's keto protocol reversed type 2 diabetes in 80 percent of patients and got 94 percent off insulin. Each one hits the same root, and blood pressure, blood fats, liver fat, and inflammation all improve at once.

3. Lustig's eight cellular pathologies

In Metabolical, Robert Lustig pushes the thesis one layer deeper. Lustig is a UCSF children's hormone doctor. His 2009 talk "Sugar: The Bitter Truth" started the modern fight against sugar. He says chronic disease is really eight things going wrong inside your cells. None of them has a clean drug target. All of them respond to food. The eight are:

1. Glycation
2. Oxidative stress
3. Mitochondrial dysfunction
4. Insulin resistance
5. Loss of membrane integrity
6. Chronic inflammation
7. Epigenetic damage
8. Autophagy failure

The diseases your doctor names sit downstream of these eight.

Glycation is the Maillard reaction (browning, like searing a steak) happening inside you. Sugars stick to your proteins and form AGEs (advanced glycation end products). AGEs stiffen tissue, scar your arteries, and trigger inflammation. Fructose glycates about 7 times faster than glucose. Its breakdown product methylglyoxal is 250 times faster.

Oxidative stress is when your cells leak reactive oxygen species (a kind of cellular exhaust) and your defenses cannot keep up. Your main defenses are glutathione, superoxide dismutase, catalase, and the Nrf2 pathway.

Mitochondrial dysfunction is when your mitochondria break down. Mitochondria are the tiny power plants inside your cells. You get fewer of them. The ones you have look fat and lazy under a microscope. They make less ATP (your cell's energy currency). Pyruvic acid backs up. Your liver turns it into fat. Your liver becomes a fat factory.

Insulin resistance is the section above.

Membrane integrity breaks down when industrial seed oils (corn, soy, canola) push omega-3 fats out of your cell membranes. The U.S. ratio of omega-6 to omega-3 has shifted from about 1:1 in the past to about 20:1 today. The ratio in your fat tissue can shift in days with diet change.

Inflammation is low-grade signaling that never shuts off. It is driven by leaky gut, dietary AGEs, palmitate (a fat from your liver), and belly fat acting like a hormone gland.

Epigenetics is the layer of chemical tags (methyl and acetyl groups) that turn your genes on and off without changing your DNA. Your mother's diet, stress, and toxin exposure can leave tags that last several generations. Your great-great-grandmother's diet helps shape yours.

Autophagy is your cell's nightly cleanup. It recycles broken proteins and worn-out mitochondria. Your brain has a similar system called the glymphatic system. Autophagy turns on with fasting, exercise, ketones, and food compounds (urolithin A from pomegranate, sulforaphane from broccoli). It shuts off with constant eating and constant insulin.

Lustig's main point: these pathways sense nutrients. They respond to what you eat, when you eat, and what your gut bacteria do with it. They do not respond well to drugs because drugs hit one target, and these pathways are wired together. Three kinase switches — PI3-kinase, AMP-kinase, and mTOR — control the network. Their eight on/off combos map to the eight pathways. This is why "eat real food" keeps working across diseases that look nothing alike on the outside.

4. Means's mitochondrial framing

Casey Means is a Stanford-trained ENT (ear, nose, and throat) surgeon. She left her surgical residency to practice functional medicine. She frames the same root one step deeper: Bad Energy. Every cell in your body — about 37 trillion of them — runs on ATP. The average adult makes about 88 pounds of ATP a day. Your mitochondria make almost all of it. When mitochondria are damaged or overloaded, your cells cannot make enough ATP to do their jobs. So they send out chemical distress signals. Chronic inflammation is your body's reply to that signal. Inflammation is not the root cause.

Means's signature stat comes from Joana Araújo and colleagues at the University of North Carolina. They used NHANES data (a U.S. health survey) and found that only 6.8 percent of U.S. adults met all five Reaven-style measures for optimal heart and metabolic health. That means 93.2 percent of U.S. adults are metabolically unhealthy. Most do not have a diagnosis yet. They have rising fasting insulin, rising HOMA-IR (a math score: fasting insulin times fasting glucose, divided by 405), and rising triglyceride-to-HDL ratios. A standard yearly checkup misses all of this. Most doctors do not order fasting insulin. The lab's "normal" range for fasting glucose runs up to 99 mg/dL.

The framing matters because it shows when you can act. Bad Energy starts years or decades before a diagnosis. Your fasting glucose stays "normal" while your fasting insulin and HOMA-IR climb. CGMs (continuous glucose monitors) catch blood-sugar spikes after meals that yearly checkups miss. The 93.2 percent figure is a measurement problem in disguise. The system catches the trunk and never the seedling.

5. Inflammation as connective tissue

The fifth strand of the thesis comes from clinical nutrition. Modern Nutrition in Health and Disease, 12th edition (2020), is the field's reference textbook. Chapter 65, "Nutrition and Inflammatory Processes," is by Philip C. Calder, the top researcher on omega-3 fat signaling. Calder gives the mechanism — resolvins, protectins, specialized pro-resolving mediators (SPMs), and NF-κB control — that the disease chapters build on.

The Calder framing makes inflammation the link across modern disease. Low-grade chronic inflammation shows up as high hs-CRP, IL-6, and TNF-α on lab tests. It plays a role in heart disease (JUPITER showed CRP-driven risk apart from LDL), most cancers (long inflammation drives colon, liver, stomach, and pancreatic tumors), brain decline (microglial firing in Alzheimer's), inflammatory bowel disease, depression (the "cytokine hypothesis"), and autoimmune disease. MNHD Chapter 90 (Jensen & Gramlich) uses the GLIM criteria for malnutrition in disease. It pairs body changes (weight loss, low BMI, less muscle) with cause (low intake or inflammation). Chapter 102 (Baracos & Kubrak) covers sarcopenic obesity — high body fat plus low muscle — as a common endpoint of long-running metabolic trouble.

Inflammation sits downstream of insulin resistance, broken mitochondria, dietary AGEs and palmitate, and a wrecked microbiome. It is also a node that spreads damage to other organs. The diet handles Calder uses are long-chain omega-3s (EPA, DHA), polyphenols, fiber, and the plant-forward patterns of MNHD Chapter 67 (Mediterranean, DASH).

6. The Means / Lustig / Taubes convergence

Three writers from three different starting points have landed on the same model. Taubes comes from journalism and the history of science. In The Case Against Sugar, he argues the Yalow-Berson 1960 paper changed everything. Rosalyn Yalow and Solomon Berson built the radioimmunoassay, a way to measure insulin in blood for the first time. Yalow won the 1977 Nobel Prize for it. The new tool showed that obese people and type 2 diabetics were not just high in glucose. They were high in insulin too. That finding rewired the obesity question from "calories in versus out" to "what is driving chronic high insulin." The answer pointed at sugar. Sugar is half glucose and half fructose. The fructose half slams the liver in one bolus and skips the brake that normally slows sugar breakdown when your cells have enough fuel.

Lustig comes from children's hormone medicine and biochemistry. He argues for the eight pathways above. He also argues that fructose acts like alcohol in the liver. About 100 percent of an oral fructose load hits your liver. It drives fat-making (de novo lipogenesis), creates uric acid, and no human cell needs it.

Means comes from clinical medicine and the money behind health care. She argues the U.S. medical system cannot prevent the syndrome by design. Every player gets paid more when you stay sick.

The overlap is clean. All three point at the same upstream inputs:

• Free fructose without fiber (sugar drinks, HFCS in processed food, fruit juice).
• Constant insulin signaling (nonstop snacking, ultra-processed carbs from waking to bedtime).
• The omega-6 to omega-3 imbalance from industrial seed oils.
• Sedentary indoor life.

The modern metabolic mess is what happens when all four inputs run for years. U.S. fructose intake has risen 700 to 3,000 percent over a century. Layer that on a 20:1 omega-6 to omega-3 ratio, nonstop insulin, and sitting all day. You get the 93.2 percent figure.

7. Treatment implications

If the thesis is right, the treatment side follows. First, drug companies cannot fix this with single-target drugs. NAFLD has no FDA-approved drug. The four lead candidates (obeticholic acid, selonsertib, elafibranor, cenicriviroc) hit 10 to 30 percent on weak surrogate endpoints. Alzheimer's has seen 146 failed drug trials at about $290 billion. You cannot drug eight linked pathways with one molecule.

Second, diet beats drugs. The Lyon Diet Heart Study (de Lorgeril et al., 1994) put heart-attack survivors on a Mediterranean diet high in alpha-linolenic acid. It cut heart events and all-cause death by 50 to 70 percent over four years. That is much larger than statins. The trial was stopped early for ethical reasons. The Newcastle 800-calorie diet (Lim, 2011) shrank pancreas and liver fat and restored beta-cell function in new type 2 diabetics. DiRECT (Lean, 2018) showed lasting remission in primary care.

Third, the upstream fixes cluster:

• Reduce constant insulin signaling: less sugar, fewer ultra-processed carbs, a 12- to 14-hour overnight gap between dinner and breakfast.
• Reduce oxidative and inflammatory load: cut industrial seed oils, raise long-chain omega-3 intake, eat plants with polyphenols and fiber.
• Build mitochondrial capacity: zone-2 cardio, lifting weights, sleep, cold exposure.

Nothing exotic. All take pressure off the same engine. The same diet pattern protects against type 2 diabetes, heart disease, several cancers, NAFLD, PCOS, and cognitive decline. They all sit downstream of one machine.

Frequently Asked Questions

Is metabolic syndrome a real diagnosis?

Yes. The NCEP ATP III criteria (any three of five: waist circumference, triglycerides, HDL, blood pressure, fasting glucose) are recognized by the AHA, IDF, and WHO, with ICD-10 code E88.81. The debate is whether the cluster shares one root cause or just shows up together.

How is metabolic syndrome different from prediabetes?

Prediabetes is defined by glucose alone (fasting 100 to 125 mg/dL or HbA1c 5.7 to 6.4 percent). Metabolic syndrome is the broader cluster — waist, blood pressure, triglycerides, HDL, glucose. It catches the same root problem earlier and across more tissues. You can have metabolic syndrome with normal fasting glucose, because high insulin hides the problem for years before glucose drifts up.

What about TOFI ("thin on the outside, fat on the inside")?

TOFI means "thin on the outside, fat on the inside." About 40 percent of normal-weight U.S. adults are metabolically unhealthy. Their body fat looks fine, but their visceral fat (around organs) and liver fat are not. BMI misses them. Waist size, fasting insulin, the triglyceride-to-HDL ratio, and ALT (your liver enzyme, a problem above 25 IU/L even though many labs flag 40) catch them. Lustig calls fasting insulin the single most useful lab test most doctors do not order.

Are GLP-1 drugs (Ozempic, Wegovy) treating the underlying problem?

Not directly. GLP-1 drugs slow stomach emptying, blunt blood sugar spikes after meals, and cut appetite. The weight loss they cause improves insulin sensitivity. But they put a chemical brake on intake. They do not fix the upstream pathway. Stop the drug and, unless your diet has changed, resistance comes back. Powerful tools, not a substitute for changing what you eat.

Why doesn't this affect everyone?

Susceptibility varies. Family history accounts for about 15 percent of risk. The rest is the world around you. South Asians get the syndrome at much lower BMI than Northern Europeans. Pancreas reserves and liver-fat thresholds vary person to person. But the 93.2 percent figure tells you "doesn't affect everyone" describes how bad and how fast — not whether you are off the hook. The slope is the same. The starting line varies.

Can children have metabolic syndrome?

Yes, and more often each year. Childhood obesity has tripled since the 1970s. NAFLD now affects up to 20 percent of U.S. kids. Lustig's WATCH clinic at UCSF was built to treat severely obese kids with adult-pattern metabolic syndrome. Type 2 diabetes now shows up in elementary-school children. Means notes that gestational diabetes (diabetes that starts during pregnancy) and obesity during pregnancy program a child for lifelong metabolic trouble through the womb environment.

Is exercise enough?

Helpful but not enough. Exercise hits about 5 of Lustig's 8 pathways (insulin resistance, mitochondria, inflammation, autophagy, oxidative-stress defense). It barely touches the other 3 (glycation, membranes, epigenetics) without diet change. Sami Inkinen — a triathlete who became prediabetic on sports drinks — is the classic case. You cannot outrun a bad diet.

What blood tests should I get?

Beyond a standard CMP and lipid panel, ask for:

• Fasting insulin (optimal 2 to 5 mIU/L; above 15 means resistance)
• HOMA-IR (insulin times glucose, divided by 405; below 1.0 is great, above 2.5 is a worry)
• hs-CRP
• HbA1c
• Triglyceride-to-HDL ratio (a stand-in for small dense LDL; below 1.5 is ideal, below 1.0 is optimal)
• Uric acid (above 5.5 mg/dL hints at mitochondrial stress)
• ALT, AST, GGT (liver fat)
• ApoB or NMR lipoprotein fractionation
• Vitamin D (40 to 60 ng/mL)
• Homocysteine

Most doctors will not order fasting insulin unless you ask. Direct-to-consumer panels (Function Health, Levels, Marek Health) make this easy.

Sources

1. Reaven, G. M. "Banting Lecture 1988: Role of insulin resistance in human disease." Diabetes, 1988;37(12):1595–1607. DOI: 10.2337/diab.37.12.1595.
2. Yalow, R. S., Berson, S. A. "Immunoassay of endogenous plasma insulin in man." Journal of Clinical Investigation, 1960;39(7):1157–1175. DOI: 10.1172/JCI104130. The radioimmunoassay that made insulin measurable; basis for Yalow's 1977 Nobel.
3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. "Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) — Adult Treatment Panel III." JAMA, 2001;285(19):2486–2497. The ATP III metabolic syndrome criteria.
4. Hu, F. B., Manson, J. E., Stampfer, M. J., et al. "Diet, lifestyle, and the risk of type 2 diabetes mellitus in women." N Engl J Med 2001;345:790–797 (and Hu's J Am Coll Nutr 2001 review of dietary patterns and chronic disease).
5. de Lorgeril, M., Renaud, S., Mamelle, N., et al. "Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease." The Lancet, 1994;343(8911):1454–1459. The Lyon Diet Heart Study.
6. Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., et al. "Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol." Diabetologia, 2011;54(10):2506–2514. The Newcastle 800-calorie study.
7. Lean, M. E. J., Leslie, W. S., Barnes, A. C., et al. "Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial." The Lancet, 2018;391(10120):541–551.
8. Araújo, J., Cai, J., Stevens, J. "Prevalence of Optimal Metabolic Health in American Adults: National Health and Nutrition Examination Survey 2009–2016." Metabolic Syndrome and Related Disorders, 2019;17(1):46–52. DOI: 10.1089/met.2018.0105. The 93.2 percent figure.
9. Lustig, R. H. Metabolical: The Lure and the Lies of Processed Food, Nutrition, and Modern Medicine (2021). Eight cellular pathologies; PI3K / AMPK / mTOR checkpoint framework; fructose-as-ethanol biochemistry.
10. Means, C., with Means, C. Good Energy: The Surprising Connection Between Metabolism and Limitless Health (2024). Bad Energy framework; mitochondrial dysfunction as upstream defect; clinical practice implications.
11. Taubes, G. The Case Against Sugar (2016). Yalow and Berson 1960; Reaven 1988 in historical context; insulin as the dominant lipogenic hormone; sugar consumption history.
12. Calder, P. C. "Nutrition and Inflammatory Processes." Chapter 65 in Ross, A. C., et al., eds., Modern Nutrition in Health and Disease, 12th edition (Wolters Kluwer, 2020). Lipid mediators, SPMs, dietary modulators of chronic inflammation.
13. Jensen, G. L., Gramlich, L. "Malnutrition in Disease and Inflammatory States." Chapter 90 in Modern Nutrition in Health and Disease, 12th edition. GLIM criteria operationalized.
14. Baracos, V. E., Kubrak, C. "Cancer Cachexia, Sarcopenia, and Sarcopenic Obesity." Chapter 102 in Modern Nutrition in Health and Disease, 12th edition.
15. Hallberg, S. J., Gershuni, V. M., Hazbun, T. L., Athinarayanan, S. J. "Reversing type 2 diabetes: a narrative review of the evidence." Nutrients, 2019;11(4):766. Virta Health protocol and outcomes.

Related glossary terms

• Metabolic syndrome
• Insulin resistance
• Hyperinsulinemia
• De novo lipogenesis
• NAFLD
• AMPK
• mTOR
• Glycation
• Oxidative stress
• Mitochondrial dysfunction